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Open acEvidence recommending antiviral therapy in hepatitis C.To the Editor:
Recently, Dr. Van der Meer and colleagues [1] discussed our sys-
tematic review of trials comparing interferon monotherapy to no
therapy for retreating individuals infected with hepatitis C virus
who had not achieved a sustained virological response (SVR)
from previous antiviral therapy [2]. Our review made several
observations: (1) retreatment with interferon monotherapy pro-
vided no relevant clinical beneﬁt; (2) while there was a statisti-
cally signiﬁcant reduction in non-fatal variceal bleeding, the
number needed to treat (NNT) was so high (NNT = 67) that the
treatment is economically unfeasible; (3) when only the low risk
of bias trials were considered, interferon treatment increased all-
cause mortality; (4) the recipients of interferon had more adverse
events; and (5) the commonly used surrogate outcome of SVR
occurred signiﬁcantly more often in the treated group.
Since interferon treatment increased SVRs without improving
clinical outcomes, the SVR was not a valid surrogate outcome in
this scenario. As such, SVR cannot be universally considered as
valid for purposes of clinical practice. We believe that, before it
can be considered a trustworthy surrogate outcome in other sce-
narios, it must be validated in those scenarios, or at least in
enough other scenarios that the single example of retreatment
of interferon monotherapy could be considered to be an outlier.
Validation of a surrogate outcome is a two-step process [3]
First, there has to be a strong and consistent association between
the surrogate outcome and the clinical one. However, association
alone is not adequate to establish validation. It also has to be
shown that improving the surrogate outcome also similarly
improves the clinical one; in other words, a treatment-related
difference between the study groups in the surrogate outcome
should be associated with a proportionate treatment-related dif-
ference in the clinical outcome. This latter step can only be dem-ted in randomized clinical trial (RCTs). Most RCTs assessing
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presumably because these outcomes require years to pass before
they begin to appear. Thus, there are limited data available to
assess the validity of the SVR. Of note, several other Cochrane
reviews also found scenarios in which an improved SVR did not
translate into a meaningful beneﬁcial clinical outcome These
included comparing interferon with or without ribavirin [4],
using ribavirin alone [5], and employing interferon in treat-
ment-naïve patients [6]. Dr. van der Meer and his colleagues cited
two of these [4,6], but only noted that the improvement in SVR
was accompanied by improvement in liver histology (another
surrogate). Not mentioned by van der Meer et al., adding ribavirin
to interferon resulted in a minimal but statistically signiﬁcant
reduction in the combined endpoint of death and hepatic mor-
bidity (0.28% reduced to 0.12%), but the NNT was 625 (compared
to an NNT of 4 for achieving an SVR) [4].
Van der Meer et al. appeared to be most concerned with our
statement that the presence of treatment harm and the failed val-
idation of SVRs ‘‘should caution us to stop advocating antiviral
interventions of any kind until we have evidence of clinical
efﬁcacy and cost-effectiveness’’ [2]. To support their argument
that SVR is a good outcome to assess antiviral therapy, they cite
a number of lines of evidence that demonstrate the association
between SVR and good outcomes. We agree with them that the
SVR is a good prognostic sign. However, the key issue is that
the SVR has not been validated as a surrogate outcome. In other
words, there are no RCTs that have shown that a treatment that
increases the number of SVRs equates with improved clinical out-
comes. Van der Meer et al. agree that this is the case.
We and van der Meer et al. also agree that most infected
patients will not develop decompensated liver disease or hepato-
cellular carcinoma and that the prognostic factors identifying
patients who are likely to achieve an SVR are also factors that
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would predict a good long-term outcome. If it is indeed true that
the vast majority (perhaps even all) of individuals achieving SVRs
were destined not to develop long-term complications of liver
disease, it would follow that SVRs would be associated with
non-progressive disease but that antiviral therapy may not pro-
vide overall beneﬁt to the treated group.
To validate the SVR as a surrogate outcome, RCTs in the future
should compare patients treated with regimens that result in lar-
ger percentages of SVRs (e.g., 90%) to untreated patients and
employ clinical events as the primary outcome. If patients in pre-
vious RCTs did not subsequently receive additional treatment, we
would encourage the authors of those trials to assess the long-
term clinical outcomes retrospectively. As of this time, treatment
advocates are supporting treatment that has no level 1 (well
designed and executed RCTs) evidence for improved clinical out-
comes, but is costly and toxic (including occasional mortal).
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To the Editor:
We thank Dr. Koretz and colleagues for responding to our apprai-
sal of their Cochrane meta-analysis [1,2], The discussion on the
clinical beneﬁts of antiviral therapy for chronic hepatitis C virus
(HCV) infection is important because physicians should be aware
of the strengths of current evidence as well as of the remaining
uncertainties.
Koretz et al. again highlight and explain that sustained viro-
logical response (SVR) is not a validated surrogate marker as sub-
stantial proof from randomized placebo-controlled trials that
antiviral therapy improves clinical outcome is lacking. As was
clearly discussed in our recent review, this is correct. We also
mentioned that the repeatedly found association between SVR
and reduced cirrhosis-related morbidity and mortality might
potentially be subject to residual confounding. Indeed, this possi-
bility cannot be excluded in the performed cohort studies. How-
ever, in light of the extensive multivariate analyses in which SVR
remained the most important factor associated with beneﬁcial
clinical outcome, we agree with others that it is hard to think
of a confounder which would completely annihilate this associa-
tion [3–5].
While recognizing that the possibility of residual confounding
remains a scientiﬁc limitation, we have indeed challenged the
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statement that no kind of antiviral therapy can currently be advo-
cated. One of the key arguments by which Koretz et al. try to sub-
stantiate this statement is the increased mortality rate among
interferon-treated patients as compared to controls, which was
observed in their meta-analysis. However, it should be clearly
mentioned that this was only found in the extended follow-up
analyses of the Hepatitis C Antiviral Long-term Treatment
Against Cirrhosis (HALT-C) trial, which almost solely drove their
meta-analyses on SVR and mortality [6]. Unfortunately, in their
response letter, Koretz et al. do not share their thoughts on the
fact that all controls in the HALT-C study received a regular pegy-
lated interferon (PegIFN) and ribavirin treatment course just prior
to randomization. Consequently, this study compared long-term
PegIFN therapy to short-term PegIFN therapy rather than to no
treatment [7]. The design of the HALT-C trial thus prohibits
extrapolation of the increased mortality rate as observed with
long-term maintenance therapy to the regular PegIFN regimens.
Therefore, this study should not have been included in the
meta-analyses.
Our review did discuss that patients treated with interferon
and ribavirin combination therapy had a beneﬁcial clinical out-
come as compared to patients treated with interferon mono ther-
apy. In fact, as the improved clinical outcome is in line with the
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